Interaction of anticancer Ru( iii ) complexes with single stranded and duplex DNA model systems
- 22 June 2015
- journal article
- research article
- Published by Royal Society of Chemistry (RSC) in Dalton Transactions
- Vol. 44 (31) , 13914-13925
Abstract
The interaction of the anticancer Ru(III) complex AziRu – in comparison with its analogue NAMI-A, currently in advanced clinical trials as an antimetastatic agent – with DNA model systems, both single stranded and duplex oligonucleotides, was investigated using a combined approach, including absorption UV-vis spectroscopy, circular dichroism (CD) and electrospray mass spectrometry (ESI-MS) techniques. UV-vis absorption spectra of the Ru complexes were recorded at different times in a pseudo-physiological solution, to monitor the ligand exchange processes in the absence and in the presence of the examined oligonucleotides. CD experiments provided information on the overall conformational changes of the DNA model systems induced by these metal complexes. UV- and CD-monitored thermal denaturation studies were performed to analyse the effects of AziRu and NAMI-A on the stability of the duplex structures. ESI-MS experiments, carried out on the oligonucleotide/metal complex mixtures under investigation, allowed us to detect the formation of stable adducts between the guanine-containing oligomers and the ruthenium complexes. These data unambiguously demonstrate that both AziRu and NAMI-A can interact with the DNA model systems. Although very similar in their structures, the two metal compounds manifest a markedly different reactivity with the examined sequences, respectively, with either a naked Ru3+ ion or a Ru(Im)3+ (Im = imidazole) fragment being incorporated into the oligonucleotide structure via stable linkages.Keywords
This publication has 41 references indexed in Scilit:
- Control of ligand-exchange processes and the oxidation state of the antimetastatic Ru(iii) complex NAMI-A by interactions with human serum albuminDalton Transactions, 2011
- Cellular uptake and subcellular distribution of ruthenium-based metallodrugs under clinical investigation versus cisplatinMetallomics, 2011
- Structure of duplex DNA containing the cisplatin 1,2-{Pt(NH3)2}2+-d(GpG) cross-link at 1.77Å resolutionJournal of Inorganic Biochemistry, 2010
- Ruthenium versus platinum: interactions of anticancer metallodrugs with duplex oligonucleotides characterised by electrospray ionisation mass spectrometryJBIC Journal of Biological Inorganic Chemistry, 2010
- Recent developments in ruthenium anticancer drugsMetallomics, 2009
- The Hydrolysis Mechanism of the Anticancer Ruthenium Drugs NAMI-A and ICR Investigated by DFT−PCM CalculationsThe Journal of Physical Chemistry B, 2008
- The resurgence of platinum-based cancer chemotherapyNature Reviews Cancer, 2007
- Dinuclear Ruthenium(II) Triple‐Stranded Helicates: Luminescent Supramolecular Cylinders That Bind and Coil DNA and Exhibit Activity against Cancer Cell LinesAngewandte Chemie International Edition, 2007
- Synthesis and Chemical−Pharmacological Characterization of the Antimetastatic NAMI-A-Type Ru(III) Complexes (Hdmtp)[trans-RuCl4(dmso-S)(dmtp)], (Na)[trans-RuCl4(dmso-S)(dmtp)], and [mer-RuCl3(H2O)(dmso-S)(dmtp)] (dmtp = 5,7-Dimethyl[1,2,4]triazolo[1,5-a]pyrimidine)Journal of Medicinal Chemistry, 2004
- Synthesis, molecular structure, and chemical behavior of hydrogen trans-bis(dimethyl sulfoxide)tetrachlororuthenate(III) and mer-trichlorotris(dimethyl sulfoxide)ruthenium(III): the first fully characterized chloride-dimethyl sulfoxide-ruthenium(III) complexesInorganic Chemistry, 1991